Insulet Corp at Nasdaq Investor Conference Transcript
Great. Good morning, everyone. Thank you for joining us for the 47th NASDAQ Conference in association with Morgan Stanley. I'm Cecilia Furlong, a Medical Device Analyst here at Morgan Stanley. It's my pleasure to have Insulet with us, CEO, Jim Hollingshead; and then also Deb Gordon, IR. Thank you both for being here with us today.
Thanks, Cecilia. It's great to be here. And is this still morning or good afternoon, everybody. It's nice to see you all here. Let me just start with a couple of comments about Insulet for those of you who may not know us. Our mission is to massively simplify the lives for people with diabetes. And we're known for the Omnipod product platform.
The Omnipod is a wearable disposable tubeless insulin delivery system. We're really excited that we've just launched the fifth generation of that product, which also includes an automated insulin delivery algorithm is a product called the
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
